Abstract:The knowledge of genomic structure of man, of Plasmodium falciparum and of its main vector Anopheles gambiae has led to great progress in the understanding of malaria pathophysiology. It may also offer new perspectives for malaria therapy vaccines or control of mosquito-borne transmission. In pathophysiology, genes encoding adhesion plasmodial proteins of their receptors were identified, as well as other genes controlling the patient immune response or the antigenic parasite variability. From a therapeutic point of view, new targets for future antimalarial drugs were identified, mainly in apicoplast (a vestige of vegetal structure incorporated by the parasite during its phylogenic evolution) and several enzymes, particularly proteases. It will be now necessary among these "promising new molecules" to select a few ones (probably no more than 5 or 6) for a pre clinical and clinical pharmaceutical development. Indeed, the industrial possibilities for developing new antimalarial drugs are evidently limited and several other antimalarial drugs are already under development. For future malaria vaccines, several new targets and antigenic proteins were also identified. As for new drugs, a complete evaluation of these antigens is absolutely necessary to select few of them for clinical development. Particularly for malaria, ADN vaccines may offer very promising perspectives with the possibility to obtain both humoral and cellular immunity and to use at the same time a panel of plasmodial antigens. It could be thus possible to obtain a simultaneous immunization against different stages of Plasmodium falciparum (sporozoites, merozoites, gametocytes) and to use, as an adjuvant, a gene encoding a viral protein or a cytokine (GMCSF). In Anopheles gambiae genome, several genes encoding for key-proteins, particularly odorant receptors necessary for blood meals, were identified. Non biting-non transmitting mosquitoes were obtained by genetic manipulation and, from an academic viewpoint, offer a very attractive new perspective for the interruption of malaria transmission. Unfortunately several practical problems remain unsolved and genetically modified mosquitoes do not survive long enough among "wild" strains. On the whole genomic and proteomic gave very exciting scientific results in malaria and, very probably the post-genomic phase will even give more new data. From a practical, medical viewpoint, it is still too early and speculative to imagine their possible applications for malaria control.

Curing mosquitoes with genetic approaches for malaria control

Genetic approaches to interfere with malaria transmission by vector mosquitoes

Genetic control of mosquitoes: population suppression strategies

Combating mosquito-borne diseases using genetic control technologies

Gene drives: an alternative approach to malaria control?

The Biological Control of the Malaria Vector

[Genomic, molecular biology and malaria: new medical perspectives?]

Advances and challenges in synthetic biology for mosquito control

Genetic engineering and bacterial pathogenesis against the vectorial capacity of mosquitoes

Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi

Transforming malaria prevention and control: the prospects and challenges of gene drive technology for mosquito management

Highly Efficient Site-Specific Mutagenesis in Malaria Mosquitoes Using CRISPR

Combining transgenesis with paratransgenesis to fight malaria

Genetic Improvements to the Sterile Insect Technique (SIT) for the Control of Mosquito Population

Changes in the microbiota cause genetically modified Anopheles to spread in a population

Driving mosquito refractoriness to Plasmodium falciparum with engineered symbiotic bacteria

CRISPR-mediated germline mutagenesis for genetic sterilization of Anopheles gambiae males

Considerations for first field trials of low-threshold gene drive for malaria vector control

Chromobacterium biopesticide overcomes insecticide resistance in malaria vector mosquitoes

Gene Drive and Symbiont Technologies for Control of Mosquito-Borne Diseases

Developing transgenic Anopheles mosquitoes for the sterile insect technique